Stock Alert: Adaptive (ADPT) down 6.60% in August 5 pre-market trading
Adaptive Biotechnologies Corp (NASDAQ: ADPT) was active in premarket trading today, Aug. 5, with shares down 6.60% from the last closing price.
The stock is down 59.52% since the start of the year, while gaining 22.15% over the past 5 days.
For technical charts, analysis and more on Adaptive, visit the company profile.
Pre-market price and movements at 06:58:34 EST.
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes that the adaptive immune system is nature’s most accurate diagnosis and treatment for most diseases, but failure to decode it has prevented the medical community from fully harnessing its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life science research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune diseases and infectious diseases. Our goal is to develop and commercialize clinical products focused on the immune system adapted to each patient.
To get more information about Adaptive Biotechnologies Corp and follow the latest company updates, you can visit the company profile page here: Adaptive Biotechnologies Corp Profile. For more financial market news, visit Equities News. Also, don’t forget to subscribe to the Daily Fix to get the best stories delivered to your inbox 5 days a week.
Sources: Symbol Info Widget is provided by TradingView based on 15 minute delayed prices. All other item data is provided by IEX Cloud on 15 minute delayed pricing or EOD company information.
Stock price data is provided by IEX Cloud on a 15 minute delayed basis. Chart price data is provided by TradingView with a 15-minute time frame.
The views and opinions expressed in this article are those of the authors and do not represent the views of equity.com. Readers should not consider any statements made by the author as formal recommendations and should consult their financial advisor before making any investment decision. To read our full statement, go to: http://www.equities.com/disclaimer
The strong dollar is a problem for equities
3 ways finance teams can manage inflation with automation
Inflation continues to drive up interest rates